M
Manzar Ashtari
Researcher at University of Pennsylvania
Publications - 120
Citations - 10386
Manzar Ashtari is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: First episode & White matter. The author has an hindex of 52, co-authored 116 publications receiving 9996 citations. Previous affiliations of Manzar Ashtari include University of Kentucky & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.
Miranda Chakos,J.A. Lieberman,Robert M. Bilder,M Borenstein,Gail Lerner,Bernhard Bogerts,Houwei Wu,Bruce J. Kinon,Manzar Ashtari +8 more
TL;DR: Caudate enlargement occurs early in the course of treatment in young first-episode schizophrenic patients, which may be a result of an interaction between neuroleptic treatment and the plasticity of dopaminergic neuronal systems in young patients.
Journal ArticleDOI
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia.
TL;DR: The results demonstrate abnormal medial temporal lobe morphology in a subgroup of patients at the onset of their illness, which might explain some of the clinical features of the disease.
Journal ArticleDOI
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation.
Philip R. Szeszko,Philip R. Szeszko,Robert H. Lipsky,Claudia Mentschel,Delbert G. Robinson,Delbert G. Robinson,Handan Gunduz-Bruce,Serge Sevy,Serge Sevy,Manzar Ashtari,Barbara Napolitano,Robert M. Bilder,John M. Kane,John M. Kane,David Goldman,Anil K. Malhotra,Anil K. Malhotra +16 more
TL;DR: The findings implicate genetic involvement of BDNF in variation of human hippocampal volume and suggest that this effect may be greater among patients compared to healthy volunteers.
Journal ArticleDOI
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett,Jean Bennett,Manzar Ashtari,Jennifer Wellman,Kathleen A. Marshall,Laura Cyckowski,Daniel C. Chung,Daniel C. Chung,Sarah McCague,Eric A. Pierce,Eric A. Pierce,Yifeng Chen,Jeannette L. Bennicelli,Xiaosong Zhu,Gui-Shuang Ying,Junwei Sun,J. Fraser Wright,Alberto Auricchio,Francesca Simonelli,Kenneth S. Shindler,Federico Mingozzi,Katherine A. High,Katherine A. High,Albert M. Maguire,Albert M. Maguire +24 more
TL;DR: The researchers report that the lack of immune response and the robust safety profile in this readministration gene therapy study may be due in part to the immune-privileged nature of the eye, and the low dose and very pure preparation of the AAV vector.
Journal ArticleDOI
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Jean Bennett,Jean Bennett,Jennifer Wellman,Kathleen A. Marshall,Sarah McCague,Manzar Ashtari,Manzar Ashtari,Julie DiStefano-Pappas,Okan U. Elci,Daniel C. Chung,Junwei Sun,Junwei Sun,J. Fraser Wright,Dominique Cross,Puya Aravand,Laura Cyckowski,Jeannette L. Bennicelli,Federico Mingozzi,Alberto Auricchio,Eric A. Pierce,Jason Ruggiero,Bart P. Leroy,Bart P. Leroy,Francesca Simonelli,Katherine A. High,Katherine A. High,Albert M. Maguire +26 more
TL;DR: To the knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye and the results highlight the use of several outcome measures and help to delineate the variables that contribute to maximal benefit from gene augmentation therapy in this disease.